Skip to main content
WAT
NYSE Industrial Applications And Services

Waters Corp Beats Q2 Guidance and Lifts Full-Year Outlook on Broad-Based Strength

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$364.69
Mkt Cap
$36.794B
52W Low
$275.05
52W High
$414.15
52W Position info
33% above low
Off High info
12% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

WAT sits 33% above its 52-week low of $275.05.

Summary

Waters Corp reported Q2 2026 revenue of $1.645B, beating the high end of guidance, with organic constant currency growth of 9%. Full-year 2026 guidance was raised to 7–9% organic revenue growth and adjusted EPS of $14.45–$14.65.

Updates

  1. · Reuters — Q2 revenue was $1.65B vs $1.62B consensus; full-year revenue guidance raised to $6.42B-$6.48B from $6.41B-$6.46B.


Key Events · Earnings and Guidance · WAT

  • Q2 Revenue Beat

    Total revenue of $1.645B surpassed the high end of guidance, with organic revenue of $828M growing 9% in constant currency.

  • Broad-Based Outperformance

    The Analytical Sciences Division delivered 8% instrument growth and double-digit chemistry consumables growth; the acquired BDS business grew 4% on a comparable basis, exceeding expectations.

  • Adjusted EPS at High End

    Adjusted EPS of $3.05 landed at the high end of the guidance range, as early cost actions offset unfavorable FX translation.

  • Full-Year Guidance Raised

    Full-year 2026 organic constant currency revenue growth guidance was raised to 7–9%, with adjusted EPS now expected at $14.45–$14.65, representing 10–12% growth.


Analysis · WAT · Industrial Applications And Services

A strong second quarter saw Waters deliver total revenue of $1.645 billion, surpassing the high end of its guidance range. Organic revenue grew 9% in constant currency, fueled by an 8% instrument gain in the Analytical Sciences Division and double-digit growth in chemistry consumables. The recently acquired Biosciences and Diagnostic Solutions business also exceeded expectations, posting 4% growth on a comparable basis—an early payoff from the 180-day revitalization plan. Adjusted EPS of $3.05 landed at the high end of guidance. Management raised full-year 2026 guidance across all metrics, now projecting 7–9% organic constant currency revenue growth and adjusted EPS of $14.45–$14.65, which represents 10–12% growth. The third-quarter outlook was equally robust, calling for 8–10% organic constant currency revenue growth and adjusted EPS of $3.95–$4.05. This broad-based outperformance and the raised guidance point to accelerating momentum in the core business and a successful integration of the BDS acquisition, despite GAAP losses from purchase accounting charges.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, WAT was trading at $364.69 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $275.05 to $414.15. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

WAT - Latest Insights

WAT
Nov 10, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $475.52
Real-time Price: $456.38 info
Change: -$19.14 (-4%) info
Market Cap: $44.889B info
WAT
Nov 03, 2026, 8:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $456.00
Real-time Price: $456.38 info
Change: +$0.380 (+0.08%) info
Market Cap: $44.889B info
WAT
Nov 03, 2026, 6:12 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $457.00
Real-time Price: $456.38 info
Change: -$0.620 (-0.14%) info
Market Cap: $44.889B info
WAT
Aug 11, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $414.59
Real-time Price: $456.38 info
Change: +$41.79 (+10%) info
Market Cap: $44.889B info
WAT
Aug 04, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $373.00
Real-time Price: $456.38 info
Change: +$83.38 (+22%) info
Market Cap: $44.889B info